AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28923223
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment modalities for hepatocellular carcinoma
Trial: 15218558
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg diclofenac sodium softgel
Trial: 15218558
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg diclofenac potassium (Cataflam)
Trial: 10845671
Drug: Prednisolone-primed IFN
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone-primed IFN treatment (Group I)
Trial: 10845671
Drug: IFN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN treatment only (Group II)
Trial: 1302763
Drug: 16.4 mg
RxNorm normalized name: rabacfosadine 16.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.4 mg iv prednisolone
Trial: 1302763
Drug: 49.2 mg
RxNorm normalized name: fusidate 49.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 49.2 mg iv prednisolone
Trial: 1302763
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (baseline)
Trial: 3886139
Drug: Fentiazac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentiazac (100 mg QID)
Trial: 3886139
Drug: Paracetamol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (500 mg QID)
Trial: 22892722
Drug: Ultra-low-dose chest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose chest computed tomography (ULD-CT) with model-based iterative reconstruction (MBIR)
Trial: 22892722
Drug: Ultra-low-dose chest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose chest computed tomography (ULD-CT)
Trial: 22892722
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose diagnostic CT (SDD-CT)
Trial: 22892722
Drug: Low-dose diagnostic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose diagnostic CT (LDD-CT)
Trial: 16841343
Drug: Fluoxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (up to 40 mg)
Trial: 11321183
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) and interferon‐alpha (IFN‐alpha) combination therapy at high dose (600 mg ZDV/6 MIU IFN‐alpha)
Trial: 11321183
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) and interferon‐alpha (IFN‐alpha) combination therapy
Trial: 11321183
Drug: Interferon‐alpha (IFN‐alpha)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐alpha (IFN‐alpha) monotherapy
Trial: 2905069
Drug: Acetazolamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500 mg daily)
Trial: 17255240
Drug: Mass oral
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass oral azithromycin distribution
Trial: 21277016
Drug: simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg daily
Trial: 20525840
Drug: Glucosamine 500
RxNorm normalized name: glucosamine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine 500 mg three times daily
Trial: 8252691
Drug: Combined supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplementation with alpha-tocopherol (800 IU/d), ascorbate (1.0 g/d), and beta carotene (30 mg/d)
Trial: 30145512
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Cognitive-Behavioral Therapy and Fluoxetine (COMB)
Trial: 22490589
Drug: Dexmedetomidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.0 µg/kg over 10 minutes, maintenance dosage 0.7 µg×kg(‐1)×h(‐1))
Trial: 17426069
Drug: Propofol target-controlled
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target-controlled infusion
Trial: 15978305
Drug: Pheniramine maleate
RxNorm normalized name: Pheniramine Maleate
DrugBank: Pheniramine (DB01620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pheniramine maleate 0.3%/naphazoline hydrochloride 0.025% ophthalmic solution
Trial: 12416598
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day of risperidone
Trial: 12416598
Drug: 4 mg/day
RxNorm normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/day of risperidone
Trial: 10599225
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs used in acute destructive pancreatitis
Trial: 1481179
Drug: Inhaled frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled frusemide (40 mg) with placebo pretreatment
Trial: 1481179
Drug: Inhaled frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled frusemide (40 mg) with indomethacin pretreatment
Trial: 1481179
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation with placebo pretreatment
Trial: 1481179
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation with indomethacin pretreatment
Trial: 30821897
Drug: Synbiotic supplement
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplement
Trial: 18622139
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 mcg once daily
Trial: 15767334
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (3 g daily, providing 1,200 mg of calcium)
Trial: 10524689
Drug: anti-TNFα monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-TNFα monoclonal antibody treatment
Trial: 7733079
Drug: Pentasa (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentasa (1 g/day)
Trial: 7733079
Drug: Cortenema (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortenema (100 mg/day)
Trial: 1345695
Drug: Preoperative artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative artificial feeding (enteral or parenteral) for 7 to 15 days
Trial: 29231363
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy group (laser and ultrashort wave treatment)
Trial: 25064594
Drug: Regular paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular paracetamol (3990 mg/day, three times per day)
Trial: 25064594
Drug: As-needed paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed paracetamol (maximum 4000 mg/day)
Trial: 25064594
Drug: Regular paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular paracetamol vs placebo
Trial: 25064594
Drug: As-needed paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed paracetamol vs placebo
Trial: 25064594
Drug: Regular paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular paracetamol vs as-needed
Trial: 15752407
Drug: Ranitidine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 50 mg every 8 hours
Trial: 9631989
Drug: Fluconazole 150
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 150 mg once weekly
Trial: 12161404
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg/day for 7 days followed by fluconazole 150 mg once weekly
Trial: 7819037
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (3,000 mg)
Trial: 2080484
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prazepam tablets
Trial: 26091386
Drug: 5% dapsone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dapsone gel
Trial: 24999283
Drug: Problematic drug
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problematic drug use identification
Trial: 24999283
Drug: Correlates of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlates of problematic drug use
Trial: 7865641
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg q.d.s. before meals
Trial: 7865641
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg q.d.s. after meals
Trial: 7865641
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg q.d.s. before meals (good compliers)
Trial: 7865641
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg q.d.s. after meals (good compliers)
Trial: 1106446
Drug: Temazepam (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (15, 20, or 30 mg in hard gelatin capsules or 20 mg in soft gelatin capsules)
Trial: 28790412
Drug: Directed degeneration
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directed degeneration method for investigating ligand recognition mechanisms of endothelin receptor type A (ETA) with endothelin-1 (ET-1)
Trial: 22165032
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with oral lefoxidine 0.2 mg three times daily after recovery from anesthesia
Trial: 12393732
Drug: PCV7 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV7 vaccine administered before transplantation and at 3 months, 6 months, and 12 months post-transplantation
Trial: 12393732
Drug: No vaccine
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vaccine administered before transplantation
Trial: 11246617
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (15 mg/day)
Trial: 9065635
Drug: Oral emedastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral emedastine difumarate
Trial: 9065635
Drug: Xiao qing
RxNorm normalized name: Xiao mai
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiao qing long tang (homeopathic decongestant)
Trial: 9065635
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate aqueous nasal spray
Trial: 9065635
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (pre-treatment measurements)
Trial: 2949309
Drug: Intravenous ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketoprofen (100 mg in 5 ml)
Trial: 2949309
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml)
Trial: 29497812
Drug: 2-L polyethylene
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L polyethylene glycol with ascorbic acid (PEG/Asc)
Trial: 27391495
Drug: Mini-plate-anchored face-mask
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-plate-anchored face-mask therapy (n = 5)
Trial: 18446020
Drug: Vit/Min plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit/Min plus 4.5 g FOS plus 200 mg fish oil-derived DHA (DHA-FOS group)
Trial: 18446020
Drug: Basic vitamin-mineral
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic vitamin-mineral supplement (Vit/Min group)
Trial: 18446020
Drug: Vit/Min plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit/Min plus 4.5 g fructo-oligosaccharide (FOS group)
Trial: 16339289
Drug: Once-monthly ibandronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly ibandronate (150 mg)
Trial: 16339289
Drug: Once-monthly ibandronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly ibandronate (100 mg)
Trial: 16339289
Drug: Once-monthly ibandronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly ibandronate (50 mg)
Trial: 16831952
Drug: Daily ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ibandronate
Trial: 8401546
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for 8 weeks
Trial: 8401546
Drug: Intensive psychological,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive psychological, pharmacologic, and experimental treatment approaches
Trial: 25618476
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy
Trial: 16481707
Drug: 5% permethrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% permethrin cream
Trial: 22905702
Drug: 1% lindane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lindane lotion
Trial: 21253453
Drug: FFNS 110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFNS 110 mcg once daily
Trial: 7854360
Drug: Whitfield's cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whitfield's cream (3% salicylic acid and 6% benzoylic acid)
Trial: 1096122
Drug: Clotrimazole cream
RxNorm normalized name: Clotrimazole Cream
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole cream
Trial: 4330318
Drug: Lysostaphin nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysostaphin nasal spray
Trial: 4330318
Drug: Neosporin ointment
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neosporin ointment
Trial: 30940887
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (1 mg/kg daily for 3–7 days)
Trial: 30940887
Drug: Periocular injection
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periocular injection of methylprednisolone (40 mg, 1–3 days before vitrectomy)
Trial: 30940887
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone in CD subsided eyes
Trial: 30940887
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone in CD persistent eyes
Trial: 30940887
Drug: Periocular injection
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periocular injection in CD subsided eyes
Trial: 30940887
Drug: Periocular injection
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periocular injection in CD persistent eyes
Trial: 26355026
Drug: High-dose lipo-PGE1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lipo-PGE1
Trial: 26355026
Drug: Low-dose lipo-PGE1
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lipo-PGE1
Trial: 23052515
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (group G)
Trial: 19692805
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment directed to the large intestine meridian (LI 8 to LI 10)
Trial: 17109680
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks
Trial: 17109680
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks
Trial: 17109680
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 1, 4, and 5)
Trial: 17109680
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 1, 4, and 5)
Trial: 17109680
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with low viraemia)
Trial: 17109680
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with low viraemia)
Trial: 17109680
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with high viraemia)
Trial: 17109680
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with high viraemia)
Trial: 17109680
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b (both doses) plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 2 and 3)
Trial: 3652000
Drug: Mitoxantrone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 10 mg/m2 single intravenous dose
Trial: 3652000
Drug: Mitoxantrone in
RxNorm normalized name: Mitoxantrone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone in five consecutive daily fractions of 2 mg/m2
Trial: 3652000
Drug: Vinblastine continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine continuous intravenous infusion of 1.2 mg/m2 daily for 5 days
Trial: 3652000
Drug: Mitoxantrone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone and vinblastine combination
Trial: 12631557
Drug: Asimadoline 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asimadoline 0.15 mg
Trial: 12950423
Drug: Asimadoline 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asimadoline 1.5 mg
Trial: 8438618
Drug: 1-3 x
RxNorm normalized name: cariprazine
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-3 x 10(9) c.f.u. of lyophilized vaccine, administered in three oral inoculations
Trial: 8438618
Drug: Single application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application of the total dose for primary immunization or booster
Trial: 3503114
Drug: Pindolol 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 1% twice daily
Trial: 22539077
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser (PDL, 595 nm) treatment
Trial: 16026014
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity training (60 minutes per week for two weekly training sessions)
Trial: 16026014
Drug: Middle intensity
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle intensity training (2 1/2 hours of training per week for 5 weekly training sessions)
Trial: 12053882
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron before anaesthesia
Trial: 12053882
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron at the end of anaesthesia